Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition | CashCropToday
0 Shares 188 Views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

November 26, 2018
188 Views

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd.

The Wayland Group is a Canadian based company that currently owns assets involved in the cultivation and processing of cannabis in Canada, Germany, and Colombia. This agreement marks the first cannabis venture the company has completed into the United Kingdom. With cannabis now legal to be prescribed as a medicine for patients in the UK,  this acquisition has gained the company a doorway into country’s distribution network.

Wayland will be completing an initial payment of 3.8 million pounds in exchange for the 51% of Theros Pharma. After certain milestones are completed about their company Wayland has agreed to provide an additional 24 million pounds to Theros. The payment will be based upon the company’s currently stock price of $1.65 per common share. The Wayland Group has been aggressively pursuing European expansion and has also recently announced that the company will expand into Italy.

“We’re proud to join with Theros on the journey to enhance lives through cannabis, now in the UK. Theros’ dedicated team of professionals and advocates, who were instrumental in achieving cannabis legalization in the UK will work with Wayland to create access to cannabis for patients and further advocate for personalized medicine,” said Wayland Chief Executive Officer Ben Ward.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
262 views
Market Watch
262 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
185 views
Manufacturing
185 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

420 Real Properties: Cultivation, Manufacturing & Distribution Facility For Sale
Market Watch
203 views
Market Watch
203 views

420 Real Properties: Cultivation, Manufacturing & Distribution Facility For Sale

Ricky M - November 21, 2018

BUSINESS FOR SALE: Licensed, Legal & Profitable Cultivation, Manufacturing & Distribution Facility in Adelanto, CA 420 Real Properties is thrilled to announce their latest business listing!  You…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: